# Multispecialty Update 2026: The Biggest Changes in My Practice Over The Last Year

**Originally Presented: Saturday, March 21, 2026**

*Wills Eye Auditorium*

**Conference Description:**
With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.

**At the conclusion of the course, participants should be able to:**
1 Identify disease states that have new treatment in ophthalmology
2 Explain new treatments in ophthalmology

**Accreditation Statement:**
The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit Statement Designation:**
Wills Eye Hospital designates this Live Activity for a maximum of 3.25 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure Statement:**
It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

| Name of individual | Individual's role in activity | Nature of Relationship(s) / Name of Ineligible Company(s) |
|---|---|---|
| Dilru C Amarasekera, MD | Faculty | Paid consultant-Microt (Relationship has ended) |
| John C Anhalt, MD | Faculty | Advisor-Johnson & Johnson (Relationship has ended) |
| Jurij R. Bilyk, MD | Faculty, Peer Reviewer, Planner | Nothing to disclose |
| Kammi B. Gunton, MD | Faculty | Nothing to disclose |

| | | |
|---|---|---|
| Tatyana Milman, MD | Faculty | Nothing to disclose |
| Bob Penne, MD | Peer Reviewer, Planner | Nothing to disclose |
| Marisa Schoen, MD | Faculty | Nothing to disclose |
| Joshua H Uhr, MD | Faculty | Public Corp Stock-Apellis Pharmaceuticals\|Consulting Fee-Bausch + Lomb |
| Alison Watson, MD | Faculty | Nothing to disclose |